Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected Patients Treated with Abacavir, Efavirenz and Nelfinavir

被引：0
|
作者：
Olga Millán
Mercé Brunet
Jaume Martorell
Felipe García
Elena Vidal
Isabel Rojo
Montserrat Plana
Teresa Gallart
Tomas Pumarola
Jose M. Miró
Jose M. Gatell
机构：
[1] Universitat de Barcelona,Servei Immunologia, Hospital Clínic, IDIBAPS
[2] Universitat de Barcelona,Servei Toxicologia, Hospital Clínic, IDIBAPS
[3] Universitat de Barcelona,Servei Infeccions, Hospital Clínic, IDIBAPS
[4] Universitate de Barcelona,Servei Microbiologia, Hospital Clínic, IDIBAPS
[5] Hospital Clinic de Barcelona,Servei Immunologia
来源：
Clinical Pharmacokinetics | 2005年 / 44卷
关键词：
Viral Load; Efavirenz; Mycophenolate Mofetil; Abacavir; Mycophenolic Acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：525 / 538
页数：13
相关论文
共 50 条
  • [31] Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
    Dailly, Eric
    Tribut, Olivier
    Tattevin, Pierre
    Arvieux, Cedric
    Perre, Philippe
    Raffi, Francois
    Jolliet, Pascale
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (07) : 523 - 526
  • [32] Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis
    Gagliardini, R.
    Fabbiani, M.
    Fortuna, S.
    Visconti, E.
    Navarra, P.
    Cauda, R.
    Colafigli, M.
    De Luca, A.
    Trecarichi, E. M.
    Di Giambenedetto, S.
    INFECTION, 2014, 42 (04) : 775 - 778
  • [33] Target plasma concentration for efavirenz in HIV-infected patients
    Pereira, S. A.
    Corte-Real, R. M.
    Branco, T.
    Germano, I.
    Lampreia, F.
    Caixas, U.
    Monteiro, E. C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 116 - 116
  • [34] Efavirenz to nevirapine switch in HIV-infected patients with dyslipidemia
    Blanco, Francisco
    AIDS REVIEWS, 2007, 9 (02) : 126 - 126
  • [35] Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis
    R. Gagliardini
    M. Fabbiani
    S. Fortuna
    E. Visconti
    P. Navarra
    R. Cauda
    M. Colafigli
    A. De Luca
    E. M. Trecarichi
    S. Di Giambenedetto
    Infection, 2014, 42 : 775 - 778
  • [36] Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
    Eric Dailly
    Olivier Tribut
    Pierre Tattevin
    Cédric Arvieux
    Philippe Perré
    François Raffi
    Pascale Jolliet
    European Journal of Clinical Pharmacology, 2006, 62 : 523 - 526
  • [37] Comment:: reasons for early abacavir discontinuation in HIV-infected patients
    Parra-Ruiz, J
    Martínez-Ramírez, M
    Muñoz-Medina, L
    Serrano-Falcón, C
    Hernández-Quero, J
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (03) : 512 - 513
  • [38] Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz
    Caso, JAA
    Prieto, JD
    Casas, E
    Sanz, J
    AIDS, 2001, 15 (11) : 1447 - 1448
  • [39] The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis
    Gupta, Samir K.
    Rosenkranz, Susan L.
    Cramer, Yoninah S.
    Koletar, Susan L.
    Szczech, Lynda A.
    Amorosa, Valerianna
    Hall, Stephen D.
    AIDS, 2008, 22 (15) : 1919 - 1927
  • [40] Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans
    Nanzigu, S.
    Eriksen, J.
    Makumbi, F.
    Lanke, S.
    Mahindi, M.
    Kiguba, R.
    Beck, O.
    Ma, Q.
    Morse, G. D.
    Gustafsson, L. L.
    Waako, P.
    HIV MEDICINE, 2012, 13 (04) : 193 - 201
12345